Results 41 to 50 of about 8,299 (247)

Pharmacokinetics of Ambroxol Sustained Release (Mucosolvan® Retard) Compared with Other Formulations in Healthy Volunteers

Pulmonary Therapy, 2020
Plain Language Summary Ambroxol is used to relieve the symptoms of respiratory conditions in which abnormal mucus secretion is a problem, including the common cold, acute and chronic bronchitis, and chronic obstructive pulmonary disease.
Celine Ollier, Ulrike Sent, Margarida Mesquita, Martin C. Michel   +3 more
doaj   +1 more source

Development and Validation of Salbutamol, Bromhexine, Ambroxol and Guauaifenesin Determination in Human Plasma by HPLC-MS/MS Method

Разработка и регистрация лекарственных средств, 2019
Introduction. Multicomponent oral drugs containing salbutamol, bromhexine, ambroxol and guaifenesin have a mucolytic, expectorant and bronchodilator effect.
T. N. Komarov, D. S. Bogdanova, O. A. Miskiv, A. V. Aleshina, I. E. Shohin, Yu. V. Medvedev, N. S. Bagaeva, I. M. Korenskaya   +7 more
doaj   +1 more source

Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells

Neurobiology of Disease, 2015
Heterozygous mutations in GBA1 gene, encoding for lysosomal enzyme glucocerebrosidase (GCase), are a major risk factor for sporadic Parkinson's disease (PD).
Giulia Ambrosi, Cristina Ghezzi, Roberta Zangaglia, Giovanna Levandis, Claudio Pacchetti, Fabio Blandini   +5 more
doaj   +1 more source

Therapy in Bronchopulmonary Diseases Associated with Increased Secretion of Viscous Sputum and Impaired Mucus Transport

Zdorovʹe Rebenka, 2015
The article deals with the problem of cough in bronchopulmonary diseases, in particular, the attention is paid to cough with increased secretion of viscous sputum, i.e., productive cough.
Yu.V. Marushko, M.H. Hrachova
doaj   +1 more source

Ambroxol

Reactions Weekly, 2006
europepmc   +2 more sources

Evaluasi Kesesuaian Penulisan Resep pada Kasus ISPA Non Pneumonia di Poli MTBS Puskesmas Kecamatan Cengkareng [PDF]

, 2017
Acute respiratory infections (ARI) is one of the major health problems in Indonesia. There are three classifications of cases of ARI, consist of pneumonia, severe pneumonia and non pneumonia. This study aimed to find an overview of the use of antibiotics
Aulia, A. A. (Annisa), Sauriasari, R. (Rani), Swastika, A. (Adisa)   +2 more
core   +2 more sources

The ongoing pursuit of neuroprotective therapies in Parkinson disease [PDF]

, 2015
Many agents developed for neuroprotective treatment of Parkinson disease (PD) have shown great promise in the laboratory, but none have translated to positive results in patients with PD.
A Alonso, A Ascherio, A Consoli, A Fitton, A Goris, A Harkavyi, A Schneeberger, A Schneider, A Zimran, A-L Mougenot, AD Wahner, AE Berman, AE Lang, AH Schapira, AHV Schapira, AHV Schapira, AL Bartels, AR Carta, AR Diani, B Pasternak, B Ritz, B Ritz, B Schütz, B Wolozin, B Zhang, BI Pérez-Revuelta, BJ Snow, C Becker, C Becker, C Hansen, C Marras, C Pifl, C Shen, C Stack, CD Ward, CM Wischik, CR Swanson, CS Chan, CS Chan, CW Olanow, CW Olanow, CW Olanow, CW Olanow, CY Chung, D Aarsland, D Devos, D Muslimovic, D Tsuang, D-K Choi, D-P Hong, DD Lofrumento, DF Tardiff, DG Parkes, Dilan Athauda, DJ Irwin, DJ Irwin, DT Dexter, DT Dexter, E Andreadou, E Bezard, E Ilijic, E Masliah, E Masliah, E Masliah, EC Hirsch, F Blandini, F Molina-Holgado, F Richter, FL Martin, FL Watson, G Bertilsson, G Costa, G Tóth, G Wu, GJ Ryan, GK Ulusoy, GW Duncan, H Braak, H Jin, H Mortiboys, HI Hurtig, I Aviles-Olmos, I Aviles-Olmos, I Bendikov-Bar, I Pedroso, J Clark, J Hippisley-Cox, J Neumann, J Pan, J Sian, J Sian-Hülsmann, J Simón-Sánchez, J Yan, J-H Kang, J-Y Li, JA Posener, JC Adair, JC O'Leary, JF Morley, JH Kordower, JJ Elm, JM Fearnley, JP Anderson, JR Colca, JR Colca, JR Colca, JS Schneider, JS Schneider, JS Schneider, JW Steele, K Imamura, K Meuer, K Okada, K Parain, K-H Jung, K-W Lee, KA Jellinger, KC Luk, L Azoulay, LA Volpicelli-Daley, LS Tain, M Asanuma, M Broadstock, M Ferwana, M Katz, M Murata, M Okada, M Quik, M Quik, M Santiago, M Selikhova, M Takanashi, MA Hely, MA Nunes, MA Schwarzschild, MA Schwarzschild, MC Hernández-Romero, ME Choudhury, ME Choudhury, MF Beal, MF Beal, MG Weisskopf, MI Ekstrand, MJ Hurley, ML Selley, ML Wahlqvist, MM Iravani, MM Khan, MT Heneka, N Boddaert, N Rampersaud, NP Visanji, O Weinreb, P Bar-On, P Brundin, P Desplats, P Riederer, P Schwingenschuh, PA Agarwal, PC Grayson, PN Tariot, PT Kotzbauer, Q Wang, R Crichton, R Duran, R Haddadi, RA Hauser, RA Hauser, RA Lawson, RB D'Agostino, RC Chang, RE Ryan, RJ Ward, S Chen, S Duty, S Fahn, S Kang, S Kim, S Mochio, S Mounayar, S Pålhagen, S Shimohama, S Suzuki, S-T Lee, SH Appel, SJ Chinta, SP Sardi, SS Jamuar, T Breidert, T Dehmer, T Foltynie, T Foltynie, T Foltynie, T Hartung, T Nakamura, T Perry, T Perry, T Yamamoto, TB Sherer, Thomas Foltynie, TJ Montine, TL Edwards, TL Spires-Jones, V Dragalin, VA Yürekli, W Jang, WJ Marks, X Chen, X Gao, X Huang, X Zhang, Y Compta, Y Wen, Y-C Lee, Y-Q Xue, ZI Alam   +215 more
core   +1 more source

The use of ambroxol in various fields of medicine outside medical indications - A Review of the Current Literature

Quality in Sport
Introduction: Ambroxol is a drug that has a multifaceted application in medicine. Its main effects are mucolytic, mucokinetic, anti-inflammatory, antioxidant and local anesthetic.
Alicja Czyszczoń, Aneta Tkaczyk, Bartosz Maczkowski, Mirosław Sołtys, Szymon Mikler, Marek Dróżdż, Wiktoria Boral, Jan Puliński, Aleksandra Przelaskowska, Wiktoria Marzec   +9 more
doaj   +1 more source

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ambroxol Hard-Boiled Lozenges in Patients with Acute Pharyngitis

Pulmonary Therapy, 2019
Introduction The aim of this study was to evaluate the efficacy and safety of a new hard-boiled lozenge formulation containing ambroxol 20 mg versus placebo for the relief of sore throat in patients with acute pharyngitis.
Rita Sousa, Deepak R. Lakha, Sandrine Brette, Simon Hitier   +3 more
doaj   +1 more source

Plasma Glucosylsphingosine in GBA1 E365K, N409S, and L483P Heterozygous Mutation Carriers

Movement Disorders, EarlyView.
Abstract Background GBA1 encodes the lysosomal enzyme glucocerebrosidase, with key substrates that include glucosylceramide and glucosylsphingosine. The E365K variant is the most common variant in GBA1 that is associated with Parkinson's disease (PD) but is not associated with Gaucher disease.
Julian Agin‐Liebes, Alexander Haimovich, Rachel Griep, Nathan Galen Hatcher, Lihang Yao, Cheryl Waters, Shalini Padmanabhan, Roy N. Alcalay   +7 more
wiley   +1 more source